Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Drug Spending By Some Insurers Hindered By Antitrust Law

This article was originally published in The Tan Sheet

Executive Summary

Statutory caps on nonprescription drug spending by not-for-profit insurers could pose a significant barrier to expanded use of over-the-counter products

You may also be interested in...



Pharmacy “Fee-For-Service” Model Could Aid Chronic-Use OTC Switches

A pharmacy "fee-for-service" model could create a "de facto third class" of drugs that would facilitate over-the-counter switches for chronic-use medications, SDM, Inc. President Bill Howard, PhD, suggested at an IIR conference on Rx-to-OTC switches in Philadelphia Nov. 20

Pravachol OTC Label Studies, Redefined Population Urged By Cmte.

Bristol-Myers Squibb's Pravachol (pravastatin) 10 mg is an attractive candidate for OTC status, but the company should first conduct additional label comprehension studies and better define the target population for the cholesterol agent, FDA advisory committee members suggested July 14.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel